Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 12:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 109 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vaginosis, Bacterial Clear all
Completed No phase listed Observational

Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization

NCT02888197
View directory record Official record
Conditions
Candidiasis, Vulvovaginal, Yeast Infection, Mycoses, Moniliasis, Vulvovaginal, Vaginitis, Monilial
Interventions
Not listed
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Sep 24, 2026, 12:45 AM EDT
Recruiting Not applicable Interventional

Clinical Study of a Vaginal Cooling Device for the Treatment of Vulvovaginal Candidiasis (VVC)

NCT06983041
View directory record Official record
Conditions
Vulvovaginal Candidiasis (VVC), Yeast Vaginitis
Interventions
vaginal cooling device
Device
Lead sponsor
Coologics, Inc
Industry
Eligibility
22 Years to 49 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
Jacksonville, Florida • Miami, Florida • Smyrna, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

NCT02237950
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole oral tablets 500mg, 1% SPL7013 Gel, Placebo gel
Drug
Lead sponsor
Starpharma Pty Ltd
Industry
Eligibility
16 Years to 45 Years · Female only
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Montgomery, Alabama • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2019 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463

NCT01812889
View directory record Official record
Conditions
Vaginal Infection
Interventions
TOL-463 Vaginal ovule, TOL-463 Vaginal gel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Sep 24, 2026, 12:45 AM EDT
Recruiting Not applicable Interventional

Clinical Protocol CERN Feasibility Study

NCT06933420
View directory record Official record
Conditions
Bacterial Vaginosis, Fungal Vaginal Infections
Interventions
Cern Device
Device
Lead sponsor
Cern Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Irvine, California • Orange, California • Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Sep 24, 2026, 12:45 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis

NCT02185456
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
750 mg metronidazole/ 200 mg miconazole vaginal suppository, Standard of care
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study

NCT00464542
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Not applicable Interventional

A Single Group Study to Evaluate the Effects of a Boric Acid Suppository on Vaginal Health.

NCT06516757
View directory record Official record
Conditions
Vaginal Health, Bacterial Vaginosis
Interventions
Boric Acid Suppository
Dietary Supplement
Lead sponsor
Love Wellness
Industry
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

NCT03562156
View directory record Official record
Conditions
Recurrent Vulvovaginal Candidiasis
Interventions
Oteseconazole (VT-1161), Placebo
Drug
Lead sponsor
Mycovia Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
25
States / cities
Birmingham, Alabama • San Diego, California • Lauderdale Lakes, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 24, 2026, 12:45 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis

NCT02376972
View directory record Official record
Conditions
BACTERIAL VAGINOSIS
Interventions
RIFAXIMIN VAGINAL TABLET 25 MG, RIFAXIMIN VAGINAL TABLET 100 MG, PLACEBO VAGINAL TABLET, METROGEL VAGINAL
Drug
Lead sponsor
Alfasigma S.p.A.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2016 · Synced Sep 24, 2026, 12:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women

NCT02272231
View directory record Official record
Conditions
Vaginosis, Bacterial
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Trial of Trimosan Gel Effect on Pessary-associated Bacterial Vaginosis

NCT01471457
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Trimo-San gel
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Sep 24, 2026, 12:45 AM EDT
Completed No phase listed Observational

Sexually Transmitted Infections Among African American Women Who Have Sex With Women

NCT01043081
View directory record Official record
Conditions
Sexually Transmitted Infections, HIV Infections
Interventions
Not listed
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 2 Interventional

Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy

NCT00153517
View directory record Official record
Conditions
Vaginosis, Bacterial, Premature Birth, Birth Weight, Chorioamnionitis
Interventions
oral versus vaginal metronidazole
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
16 Years and older · Female only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Treatment of Bacterial Vaginosis

NCT00324818
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
metronidazole and azithromycin
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 24, 2026, 12:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing

NCT00978848
View directory record Official record
Conditions
Trichomonas Vaginitis, Chlamydia Trachomatis, Neisseria Gonorrhoeae Infection
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
15 Years and older · Female only
Enrollment
305 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis

NCT03091777
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
GDC-229, Metronidazole Vaginal Gel 0.75%, Placebo
Drug
Lead sponsor
Balmoral Medical company
Industry
Eligibility
18 Years and older · Female only
Enrollment
871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 1Phase 2 Interventional

Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis

NCT01020396
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older · Female only
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
37
States / cities
Huntsville, Alabama • Fountain Valley, California • Washington D.C., District of Columbia + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

TOL-463 Phase 2 Study for Vaginitis

NCT02866227
View directory record Official record
Conditions
Bacterial Vaginosis, Vulvovaginal Candidiasis
Interventions
TOL-463
Drug
Lead sponsor
Toltec Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Birmingham, Alabama • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 24, 2026, 12:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis

NCT02203942
View directory record Official record
Conditions
Bacterial Vaginosis, Vulvovaginal Candidiasis, Trichomoniasis
Interventions
NAAT testing
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp

NCT06954493
View directory record Official record
Conditions
Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis
Interventions
Ibrexafungerp
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Rogers, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Sep 24, 2026, 12:45 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Diagnosing Bacterial Vaginosis/Vaginitis (BV) Using the Gynecologene Test Method

NCT02558179
View directory record Official record
Conditions
Vaginosis, Bacterial
Interventions
Not listed
Lead sponsor
American International Biotechnology
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
4
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 24, 2026, 12:45 AM EDT
Terminated Phase 4 Interventional Results available

A Randomized Controlled Trial of Treatment of Bacterial Vaginosis

NCT04578015
View directory record Official record
Conditions
Bacterial Vaginoses
Interventions
Metronidazole, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 24, 2026, 12:45 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Garden of Life Once Daily Women's Probiotic: Vaginal pH and Quality of Life Study

NCT05330091
View directory record Official record
Conditions
Vaginal Health
Interventions
Once Daily Women's Probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Garden of Life, LLC
Industry
Eligibility
19 Years to 70 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Wellington, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Sep 24, 2026, 12:45 AM EDT